TLSA ▲ +2.9% - Tiziana Life Sciences Ltd
$TLSA - Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
16-OCT-2026 07:00 AM ET
Share this post
More filings for $TLSA
TLSA ▲ +8.9% - Tiziana Life Sciences LtdNov 2, 2026TLSA ▲ +1.0% - Tiziana Life Sciences LtdOct 21, 2026TLSA ▲ +6.3% - Tiziana Life Sciences LtdSep 30, 2026
View full $TLSA filing history →💬 Comments
Loading comments…
Leave a comment